Literature DB >> 26963143

Beta cell specific probing with fluorescent exendin-4 is progressively reduced in type 2 diabetic mouse models.

Janne Lehtonen1, Lauge Schäffer2, Morten Grønbech Rasch3, Jacob Hecksher-Sørensen1, Jonas Ahnfelt-Rønne1.   

Abstract

Probes based on GLP-1R agonist exendin-4 have shown promise as in vivo β cell tracers. However, questions remain regarding the β cell specificity of exendin-4 probes, and it is unclear if the expression levels of the GLP-1R are affected in a type 2 diabetic state. Using in vivo probing followed by ex vivo imaging we found fluorescent exendin-4 probes to distinctly label the pancreatic islets in mice in a Glp-1r dependent manner. Furthermore, a co-localization study revealed a near 100 percent β cell specificity with less than one percent probing in other analyzed cell types. We then tested if probing was affected in models of type 2 diabetes using the Lepr(db/db) (db/db) and the Diet-Induced Obese (DIO) mouse. Although nearly all β cells continued to be probed, we observed a progressive decline in probing intensity in both models with the most dramatic reduction seen in db/db mice. This was paralleled by a progressive decrease in Glp-1r protein expression levels. These data confirm β cell specificity for exendin-4 based probes in mice. Furthermore, they also suggest that GLP-1R targeting probes may provide a tool to monitor β cell function rather than mass in type 2 diabetic mouse models.

Entities:  

Keywords:  Glp-1 receptor; exendin-4; imaging; islets; type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26963143      PMCID: PMC4878261          DOI: 10.1080/19382014.2015.1137415

Source DB:  PubMed          Journal:  Islets        ISSN: 1938-2014            Impact factor:   2.694


  42 in total

1.  The smooth fractionator.

Authors:  H J G Gundersen
Journal:  J Microsc       Date:  2002-09       Impact factor: 1.758

2.  GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts.

Authors:  Gang Xu; Hideaki Kaneto; Maria D Lopez-Avalos; Gordon C Weir; Susan Bonner-Weir
Journal:  Diabetes Res Clin Pract       Date:  2006-01-06       Impact factor: 5.602

3.  The glucagon-like peptide-1 receptor--or not?

Authors:  Charles Pyke; Lotte Bjerre Knudsen
Journal:  Endocrinology       Date:  2013-01       Impact factor: 4.736

4.  Beta cell imaging - a key tool in optimized diabetes prevention and treatment.

Authors:  Martin Gotthardt; Decio L Eizirik; Miriam Cnop; Maarten Brom
Journal:  Trends Endocrinol Metab       Date:  2014-04-11       Impact factor: 12.015

5.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

Authors:  L A Scrocchi; T J Brown; N MaClusky; P L Brubaker; A B Auerbach; A L Joyner; D J Drucker
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

6.  Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.

Authors:  K Moens; H Heimberg; D Flamez; P Huypens; E Quartier; Z Ling; D Pipeleers; S Gremlich; B Thorens; F Schuit
Journal:  Diabetes       Date:  1996-02       Impact factor: 9.461

7.  Expression of the GLP-1 receptor in mouse, rat, and human pancreas.

Authors:  Ditte Tornehave; Peter Kristensen; John Rømer; Lotte Bjerre Knudsen; R Scott Heller
Journal:  J Histochem Cytochem       Date:  2008-06-09       Impact factor: 2.479

8.  Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.

Authors:  Olof Eriksson; Irina Velikyan; Ram K Selvaraju; Fouad Kandeel; Lars Johansson; Gunnar Antoni; Barbro Eriksson; Jens Sörensen; Olle Korsgren
Journal:  J Clin Endocrinol Metab       Date:  2014-02-10       Impact factor: 5.958

9.  Beta-cell failure in diet-induced obese mice stratified according to body weight gain: secretory dysfunction and altered islet lipid metabolism without steatosis or reduced beta-cell mass.

Authors:  Marie-Line Peyot; Emilie Pepin; Julien Lamontagne; Martin G Latour; Bader Zarrouki; Roxane Lussier; Marco Pineda; Thomas L Jetton; S R Murthy Madiraju; Erik Joly; Marc Prentki
Journal:  Diabetes       Date:  2010-06-14       Impact factor: 9.461

10.  Evaluation of an [(18)F]AlF-NOTA Analog of Exendin-4 for Imaging of GLP-1 Receptor in Insulinoma.

Authors:  Dale O Kiesewetter; Ning Guo; Jinxia Guo; Haokao Gao; Lei Zhu; Ying Ma; Gang Niu; Xiaoyuan Chen
Journal:  Theranostics       Date:  2012-10-17       Impact factor: 11.556

View more
  4 in total

Review 1.  Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation.

Authors:  Brent A McLean; Chi Kin Wong; Jonathan E Campbell; David J Hodson; Stefan Trapp; Daniel J Drucker
Journal:  Endocr Rev       Date:  2021-03-15       Impact factor: 19.871

Review 2.  Exendin-4 analogs in insulinoma theranostics.

Authors:  Tom J P Jansen; Sanne A M van Lith; Marti Boss; Maarten Brom; Lieke Joosten; Martin Béhé; Mijke Buitinga; Martin Gotthardt
Journal:  J Labelled Comp Radiopharm       Date:  2019-08       Impact factor: 1.921

3.  Expanded LUXendin Color Palette for GLP1R Detection and Visualization In Vitro and In Vivo.

Authors:  Julia Ast; Alissa N Novak; Tom Podewin; Nicholas H F Fine; Ben Jones; Alejandra Tomas; Ramona Birke; Kilian Roßmann; Bettina Mathes; Jenny Eichhorst; Martin Lehmann; Amelia K Linnemann; David J Hodson; Johannes Broichhagen
Journal:  JACS Au       Date:  2022-04-04

4.  Development and characterisation of a novel glucagon like peptide-1 receptor antibody.

Authors:  Emma K Biggs; Lihuan Liang; Jacqueline Naylor; Shimona Madalli; Rachel Collier; Matthew P Coghlan; David J Baker; David C Hornigold; Peter Ravn; Frank Reimann; Fiona M Gribble
Journal:  Diabetologia       Date:  2017-11-09       Impact factor: 10.122

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.